glp-1 препараты Агонисты рецепторов глюкагоноподобного пептида (ГПП) - список препаратов из 15.03 входит в группу клинико-фармакологических указателей (КФУ) 15 Гипогликемический препарат. Агонист рецепторов глюкагоноподобного

Sustainable weight maintenance after Zepbound requires permanent lifestyle modifications rather than temporary dietary changes

Combining retatrutide with lifestyle changes such as diet and exercise enhances effectiveness

When adding a GLP-1 to an existing Tresiba regimen, most guidelines recommend reducing the Tresiba dose by approximately 20% to avoid hypoglycemia as the GLP-1 begins its own glucose-lowering effects

I am confident the pharmaceutical industry will not be funding these trials

With newer GLP-1based therapies now emerging, the field has an opportunity to test whether different drugs in this class have distinct effects on aging biology and to identify which patients may benefit most. Larger clinical trials will be needed to confirm these findings, determine how long the effects persist, and establish optimal dosing strategies and treatment durations for both people with HIV and the broader population

Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al